Humacyte Stock Earnings Estimates Increased by HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – HC Wainwright lifted their FY2026 earnings estimates for Humacyte in a research report issued to clients and investors on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.39) per share for the year, up from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2026 earnings at ($0.10) EPS, Q1 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.11) EPS.

HUMA has been the topic of a number of other reports. Cantor Fitzgerald set a $1.00 price target on Humacyte in a research report on Thursday. BTIG Research restated a “buy” rating and set a $2.00 price objective on shares of Humacyte in a research report on Tuesday. Barclays upped their price objective on Humacyte from $0.50 to $0.60 and gave the stock an “equal weight” rating in a research note on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research note on Friday, October 2nd. Finally, Wall Street Zen lowered Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.48.

Humacyte Stock Performance

Shares of HUMA stock opened at $0.60 on Friday. The company has a market cap of $165.40 million, a P/E ratio of -1.35 and a beta of 2.64. The business has a 50 day moving average of $0.49 and a two-hundred day moving average of $0.78. Humacyte has a 52 week low of $0.34 and a 52 week high of $1.52. The company has a quick ratio of 5.74, a current ratio of 3.34 and a debt-to-equity ratio of 3.65.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Humacyte had a negative return on equity of 612.88% and a negative net margin of 3,955.05%. The business had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new position in Humacyte in the 2nd quarter worth about $4,700,000. BlackRock Inc. acquired a new position in shares of Humacyte during the second quarter worth approximately $3,777,000. GSA Capital Partners LLP acquired a new position in shares of Humacyte during the second quarter worth approximately $785,000. Private Advisor Group LLC acquired a new position in shares of Humacyte during the third quarter worth approximately $491,000. Finally, State Street Corp grew its holdings in Humacyte by 6.9% in the 3rd quarter. State Street Corp now owns 900,646 shares of the company’s stock worth $466,000 after buying an additional 58,109 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

Recent Humacyte Headlines

Here are a few of the latest headlines about HUMA:

• Positive Sentiment: Humacyte plans to present five ATEV and Symvess updates at the VEITHsymposium, including interim Phase 3 data in women receiving hemodialysis and integrated results from three dialysis-access trials. The company also expects to submit a supplemental BLA for hemodialysis access in November. The presentations may draw attention to its pipeline, though the data have not yet been presented. Humacyte VEITHsymposium announcement
• Positive Sentiment: StoneX reiterated its “Speculative Buy” rating, offering a supportive analyst view, although the reiteration itself is not a new upgrade. StoneX rating coverage
• Negative Sentiment: The broker cut its Q3 and Q4 2027 forecasts by $0.01 per share each, lowered FY2027 estimates to a loss of $0.31 per share from $0.30, and reduced its FY2028 estimate to a loss of $0.11 from $0.07. These changes suggest weaker expected earnings further out.

About Humacyte

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.